Variability in Therapy Outcomes Signals Need for Better Treatments in CLL
-
National Amyloidosis Awareness Month: Expert Says Future of Treatment Is BrightAmyloidosis, which has several types, is diagnosed in at least 4000 Americans per year. -
More PAH Therapies Than Ever Before, Yet Time to Diagnosis Hasn’t ImprovedThe number of treatments for PAH continues to rise, but it still takes an an average of 3 years from symptom onset to diagnosis. -
Colorado-Based ‘Can Do MS’ Helps People With Multiple Sclerosis Live Healthier LivesCan Do MS provides free programs on topics such as nutrition, exercise, MS symptoms, relationships, and employment. -
Smoking and Air Pollution May Exacerbate MDS and Shorten LifespanBlack carbon and PM2.5, toxins with known links to cancers, correlated highly with MDS disease severity scores in a New York study. -
Rare Disease Doctors Tout Value of Social Media While Warning of Online MisinformationThe average American has 7.1 social media accounts, according to industry statistics.
-
Lessons Learned Managing Infusion Treatments for MGGetting regular infusion treatments is a common experience for patients with myasthenia gravis (MG).March 25, 2025 -
Clarifying the Link Between Diet and Multiple SclerosisMany research studies have emphasized a possible connection between gut microbiome, diet, and multiple sclerosis (MS).March 24, 2025
-
A Patient With CIDP Shares the Emotional Toll of Delivering Bad NewsWhen I was finally diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) and started treatment, the hope came back a bit.March 24, 2025 -
Ways to Keep Healthy Friendships Living With Pompe DiseaseI was diagnosed with Pompe disease at age 12.March 24, 2025
-
Is FNAIT Screening Cost-Effective and Feasible?Researchers from The Netherlands suggest that targeted FNAIT screening may be both cost-effective and feasible. -
The Amyloid-Avid Tracer DPD May Be a Promising Tool for Measuring Deposits in ATTRThis article explores the potential of 99mTc-DPD SPECT/CT in assessing severity and guiding treatment in patients with ATTR-PN and ATTR-CM. -
Risk-Benefit Profile of Emicizumab in Treating Acquired Hemophilia AAlthough generally safe, emicizumab should be used with caution, especially in patients with high cardiovascular risk. -
Inhibiting Factor XII Activation as a Therapeutic Strategy in HAEThe targeting of factor XII activation is a key strategy in offering long-term prophylaxis to patients with hereditary angioedema. -
Assessing the Role of Physical Training in CLLExercise programs can be feasible and effective in improving health parameters among patients with chronic lymphocytic leukemia (CLL).
- Achondroplasia
- Acute Lymphoblastic Leukemia
- Alagille Syndrome
- Alpha-1 Antitrypsin Deficiency
- ANCA-Associated Vasculitis
- Cholangiocarcinoma
- Chronic Inflammatory Demyelinating Polyneuropathy
- Chronic Lymphocytic Leukemia
- Cold Agglutinin Disease
- Cystic Fibrosis
- Diffuse Large B-Cell Lymphoma
- Dravet Syndrome
- Duchenne Muscular Dystrophy
- Fetal and Neonatal Alloimmune Thrombocytopenia
- Friedreich Ataxia
- Gastrointestinal Stromal Tumor
- Generalized Pustular Psoriasis
- Hemolytic Disease of the Fetus and Newborn
- Hemophilia
- Hereditary Angioedema
- Huntington Disease
- Idiopathic Pulmonary Fibrosis
- IgG4-Related Disease
- Immune Thrombocytopenia
- Lennox-Gastaut Syndrome
- Long Chain Fatty Acid Oxidation Disorder
- Lysosomal Acid Lipase Deficiency
- Medullary Thyroid Carcinoma
- Multiple Sclerosis
- Myasthenia Gravis
- Myelodysplastic Syndromes
- Myelofibrosis
- Neuromyelitis Optica Spectrum Disorder
- Paroxysmal Nocturnal Hemoglobinuria
- Pompe Disease
- Prader-Willi Syndrome
- Primary Biliary Cholangitis
- Primary Central Nervous System Lymphoma
- Pulmonary Arterial Hypertension
- Sickle Cell Disease
- Spinal Muscular Atrophy
- Systemic Mastocytosis
- Systemic Sclerosis
- Transthyretin Amyloid Polyneuropathy
- Transthyretin-Mediated Amyloid Cardiomyopathy
- Wilson Disease
